featured
Identification of Patients With Ovarian Cancer With Highest Benefit From First-Line Bevacizumab Based on Their Tumor-Intrinsic Chemosensitivity
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study
J. Clin. Oncol 2022 Oct 17;[EPub Ahead of Print], B You, C Purdy, LJ Copeland, EM Swisher, MA Bookman, G Fleming, R Coleman, LM Randall, KS Tewari, BJ Monk, RS Mannel, JL Walker, F Cappuccini, D Cohn, M Muzaffar, D Mutch, A Wahner-Hendrickson, L Martin, O Colomban, RA BurgerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.